Tag Archives: Servier

October, 2018

July, 2018

June, 2018

April, 2018

  • 16 April

    Shire Sells Oncology Business to Servier for $2.4 Billion

    Dublin, Ireland – April 16, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) the leading global biotechnology company focused on rare diseases announces today that it has entered into a definitive agreement with Servier S.A.S. (“Servier”) to sell its Oncology business for $2.4 billion. Shire’s Oncology business includes in-market products ONCASPAR® …

July, 2017

  • 28 July

    Servier Licenses GLPG1972 in Osteoarthritis from Galapagos

    28 July 2017 – As a result of their research collaboration, Servier announces today that it has exercised its option to develop novel osteoarthritis molecule GLPG1972/S201086 from Galapagos NV (Euronext/NASDAQ: GLPG), thus obtaining global commercial rights outside the U.S. Osteoarthritis (OA) is a highly prevalent and disabling pathology, considered as …

November, 2015

  • 19 November

    Servier and Pfizer Get Rights to Cellectis CAR-T Therapy

    November 19, 2015 – New York (USA) and Suresnes (France) – Cellectis (Alternext: ALCLS; Nasdaq: CLLS) and Servier today announced that they signed an amendment to their existing collaboration agreement from February 2014 especially for UCART19, a TALEN® gene-edited allogeneic Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy. Under this amendment, Servier …